Clinical Trials /

Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03853707

Description:

This phase I/II trial studies best dose of ipatasertib and how well it works with carboplatin with or without paclitaxel in treating patients with triple negative breast cancer that has spread to other places in the body. Ipatasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving ipatasertib and carboplatin with or without paclitaxel will work better in treating patients with triple negative breast cancer.

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 1/Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer
  • Official Title: A Phase I/IB Study of Ipatasertib in Combination With Carboplatin or Carboplatin/Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Clinical Trial IDs

  • ORG STUDY ID: 18496
  • SECONDARY ID: NCI-2019-00465
  • SECONDARY ID: 18496
  • NCT ID: NCT03853707

Conditions

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Estrogen Receptor Negative
  • HER2/Neu Negative
  • Metastatic Triple-Negative Breast Carcinoma
  • Progesterone Receptor Negative
  • Prognostic Stage IV Breast Cancer AJCC v8

Interventions

DrugSynonymsArms
CarboplatinBlastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, RibocarboSchedule A (ipatasertib, carboplatin, paclitaxel)
IpatasertibGDC-0068, RG-7440Schedule A (ipatasertib, carboplatin, paclitaxel)
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol KonzentratSchedule A (ipatasertib, carboplatin, paclitaxel)

Purpose

This phase I/II trial studies best dose of ipatasertib and how well it works with carboplatin with or without paclitaxel in treating patients with triple negative breast cancer that has spread to other places in the body. Ipatasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving ipatasertib and carboplatin with or without paclitaxel will work better in treating patients with triple negative breast cancer.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the recommended phase II dose of ipatasertib plus either carboplatin or
      carboplatin/paclitaxel in patients with metastatic triple negative breast cancer (TNBC).
      (Phase I) II. To obtain initial evidence of activity by examining progression free survival
      for each dose regimen. (Phase IB)

      SECONDARY OBJECTIVES:

      I. To confirm the recommended phase II dose (RPIID) safety in expanded cohort by evaluating
      toxicities and confirm tolerability of the combinations.

      II. To obtain evidence of activity by examining response rate based on Response Evaluation
      Criteria in Solid Tumors (RECIST) 1.1.

      III. To evaluate clinical benefit rate (CBR), event-free survival, time-to-treatment failure
      and overall survival.

      IV. Further describe the cumulative toxicities (Common Terminology Criteria for Adverse
      Events [CTCAE] 5.0) of the combinations.

      V. To evaluate patient's quality of life (QOL).

      EXPLORATORY OBJECTIVES:

      I. To evaluate the progression-free survival and overall survival, based on the genomic
      alterations including PIK3CA/AKT/PTEN alterations and BRCA status.

      II. To study the association of TNBC messenger ribonucleic acid (mRNA) expression profiling
      including Vanderbilt molecular subtype and treatment response.

      III. To study the association of stool microbiome, calprotectin with diarrhea. IV. To study
      peripheral blood circulating tumor deoxyribonucleic acid (DNA). V. To study therapy
      resistance by analyzing tumor genomics and transcriptome analysis.

      OUTLINE: This is a phase I, dose-escalation trial of ipatasertib, followed by a phase II
      trial. Patients are randomized or assigned to 1 of 2 treatment schedules depending on
      available slots.

      SCHEDULE A: Patients receive ipatasertib orally (PO) once daily (QD) on days 1-28. Patients
      also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes
      on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease
      progression or unacceptable toxicity.

      SCHEDULE B: Patients receive ipatasertib PO QD on days 1-28. Patients also receive
      carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28
      days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 36 months.
    

Trial Arms

NameTypeDescriptionInterventions
Schedule A (ipatasertib, carboplatin, paclitaxel)ExperimentalPatients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
  • Carboplatin
  • Ipatasertib
  • Paclitaxel
Schedule B (ipatasertib and carboplatin)Active ComparatorPatients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
  • Carboplatin
  • Ipatasertib

Eligibility Criteria

        Inclusion Criteria:

          -  Signed informed consent form

          -  Ability to comply with the study protocol, in the investigator's judgment

          -  Histologically or cytologically confirmed triple negative breast cancer defined by
             estrogen receptor (ER) or progesterone receptor (PR) < 10% by immunohistochemistry
             (IHC) and HER2 negative defined by current American Society of Clinical
             Oncology/College of American Pathologists (ASCO/CAP) guideline

          -  Disease progression during or following treatment with up to 2 lines of chemotherapy
             and/or biological targeted therapy for metastatic TNBC

          -  Measurable or non-measurable but evaluable disease per RECIST version (v) 1.1
             (previously irradiated lesions can be considered as measurable disease only if
             progressive disease has been unequivocally documented at that site since radiation)

          -  Baseline tissue requirement:

               -  A formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block
                  (preferred) or at least 20 x 5um slides containing unstained, freshly cut, serial
                  sections must be collected along with an associated pathology report prior to
                  study enrollment

               -  If only 10-19 slides are available, the patient may still be eligible for the
                  study, after principal investigator approval has been obtained

               -  If archival tumor tissue is unavailable or is determined to be unsuitable for
                  required testing, tumor tissue must be obtained from a biopsy performed at
                  screening

               -  A biopsy may also be performed at screening if a patient's archival tissue test
                  results do not meet eligibility criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Life expectancy >= 3 months

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1,500/uL) without granulocyte
             colony-stimulating factor support (obtained within 14 days prior to initiation of
             study treatment)

          -  Platelet count >= 100 x 10^9/L (100,000/uL) without transfusion (obtained within 14
             days prior to initiation of study treatment)

          -  Hemoglobin >= 9 mg/dL (9 mg/dL) (patients may be transfused to meet this criterion)
             (obtained within 14 days prior to initiation of study treatment)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper
             limit of normal (ULN) (obtained within 14 days prior to initiation of study
             treatment), with the following exception:

               -  Patients with documented liver or bone metastases may have AST and ALT =< 5 x ULN

          -  Alkaline phosphatase (ALP) =< 2 x ULN (obtained within 14 days prior to initiation of
             study treatment), with the following exceptions:

               -  Patients with known liver involvement may have ALP =< 5 x ULN

               -  Patients with known bone involvement may have ALP =< 7 x upper limit (UL)

          -  Serum bilirubin =< 1.5 x ULN (obtained within 14 days prior to initiation of study
             treatment) with the following exception:

               -  Patients with known Gilbert disease: serum bilirubin level =< 3 x ULN

          -  Serum creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min (calculated using
             the Cockcroft-Gault formula) (obtained within 14 days prior to initiation of study
             treatment)

          -  Partial thromboplastin time (PTT) (or activated partial thromboplastin time [aPTT])
             and international normalized ratio (INR) =< 1.5 x ULN (except for patients receiving
             anticoagulation therapy) (obtained within 14 days prior to initiation of study
             treatment)

               -  Patients receiving heparin treatment should have a PTT (or aPTT) between 1.5 and
                  2.5 x ULN (or patient value before starting heparin treatment). Patients
                  receiving coumarin derivatives should have an INR between 2.0 and 3.0 assessed in
                  two consecutive measurements 1 to 4 days apart

          -  Fasting total glucose =< 150 mg/dL (obtained within 14 days prior to initiation of
             study treatment)

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per
             year during the treatment period and for 6 months after the last dose of study
             treatment. Women must refrain from donating eggs during this same period.

               -  A woman is considered to be of childbearing potential if she is post-menarcheal,
                  has not reached a postmenopausal state (>= 12 continuous months of amenorrhea
                  with no identified cause other than menopause), and has not undergone surgical
                  sterilization (removal of ovaries and/or uterus)

               -  Examples of contraceptive methods with a failure rate of < 1% per year include
                  bilateral tubal ligation, male sterilization, hormonal contraceptives that
                  inhibit ovulation, hormone- releasing intrauterine devices, and copper
                  intrauterine devices

               -  The reliability of sexual abstinence should be evaluated in relation to the
                  duration of the clinical trial and the preferred and usual lifestyle of the
                  patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post
                  ovulation methods) and withdrawal are not acceptable methods of contraception

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             a condom, and agreement to refrain from donating sperm, as defined below:

               -  With female partners of childbearing potential or pregnant female partners, men
                  must remain abstinent or use a condom during the treatment period and for 6
                  months after the last dose of study treatment to avoid exposing the embryo. Men
                  must refrain from donating sperm during this same period

               -  The reliability of sexual abstinence should be evaluated in relation to the
                  duration of the clinical trial and the preferred and usual lifestyle of the
                  patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post
                  ovulation methods) and withdrawal are not acceptable methods of contraception

        Exclusion Criteria:

          -  Inability to comply with study and follow-up procedures

          -  >= grade 2 toxicities from previous treatment, not recovered to =< grade 1 at study
             entry

          -  Prior exposure to PI3K/AKT/mTOR pathway inhibitors including but not limited to
             everolimus, ipatasertib, gedatolisib or alpelisib etc

          -  Prior exposure to carboplatin for treatment of metastatic TNBC not allowed; prior
             treatment of carboplatin as neoadjuvant or adjuvant therapy allowed if last dose of
             therapy completed >= 12 months prior to initiation of the current study

          -  Prior exposure to paclitaxel for treatment of metastatic TNBC not allowed for
             carboplatin/paclitaxel arm; prior treatment of paclitaxel as neoadjuvant or adjuvant
             therapy allowed if last dose of therapy completed >= 12 months prior to initiation of
             the current study

          -  Known allergy or hypersensitivity to any component of carboplatin and/or paclitaxel
             formulation

          -  Known severe allergic reactions to cisplatin or other platinum-containing compounds or
             mannitol

          -  History of malabsorption syndrome or other condition that would interfere with enteral
             absorption or results in the inability or unwillingness to swallow pills

          -  Active infection requiring systemic anti-microbial treatment (including antibiotics,
             anti-fungals, and anti-viral agents)

          -  Known brain metastasis or leptomeningeal metastasis from metastatic breast cancer

          -  Known human immunodeficiency virus (HIV) infection

          -  Known clinically significant history of liver disease consistent with Child-Pugh class
             B or C, including active viral or other hepatitis (e.g., positive for hepatitis B
             surface antigen [HBsAg] or hepatitis C virus [HCV] antibody at screening), current
             drug or alcohol abuse, or cirrhosis

               -  Patients with past hepatitis B virus (HBV) infection or resolved HBV infection
                  (defined as having a negative HBsAg test and a positive hepatitis B core antibody
                  [HBcAb] test, accompanied by a negative HBV deoxyribonucleic acid [DNA] test) are
                  eligible

               -  Patients positive for HCV antibody are eligible only if polymerase chain reaction
                  (PCR) is negative for HCV ribonucleic acid (RNA)

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 1 of cycle 1 or anticipation of need for a major surgical procedure
             during the course of the study

               -  Placement of a vascular access device is not considered major surgery

          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within
             28 days after the last dose of ipatasertib and within 6 months after the last dose of
             paclitaxel, whichever occurs later

               -  Women of childbearing potential (who are not postmenopausal with >= 12 months of
                  non-therapy induced amenorrhea nor surgically sterile) must have a negative serum
                  pregnancy test result either within 96 hours prior to initiation of study drug,
                  or within 7 days of day 1, cycle 1 (in this case, confirmed by a negative urine
                  pregnancy test result on day 1 of cycle 1 prior to dosing)

          -  New York Heart Association class II, III, or IV heart failure; left ventricular
             ejection fraction < 50%; or active ventricular arrhythmia requiring medication

          -  Current unstable angina or history of myocardial infarction within 6 months prior to
             day 1 of cycle 1

          -  Congenital long QT syndrome or screening QT interval corrected using Fridericia's
             formula (QTcF) > 480 milliseconds

          -  History or presence of an abnormal electrocardiogram (ECG) that is clinically
             significant in the investigator's opinion (including complete left bundle branch
             block, second- or third-degree heart block, or evidence of prior myocardial
             infarction)

          -  Need for chronic corticosteroid therapy of >= 10 mg of prednisone per day or an
             equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a
             chronic disease

          -  Treatment with approved or investigational cancer therapy within 14 days prior to day
             1 of cycle 1

          -  Patients with a prior diagnosis of malignancy except non-melanomatous skin cancer
             treated >= 5 years ago are eligible, provided that they have not received prior
             taxanes or carboplatin as part of their prior treatment regimen, and that they meet
             all eligibility criteria

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of
             a disease or condition that contraindicates the use of an investigational drug or that
             may affect the interpretation of the results or render the patient at high risk from
             treatment complications

          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within
             6 month after the last dose of study treatment

               -  Women of childbearing potential must have a negative serum pregnancy test result
                  within 14 days prior to initiation of study treatment

          -  IPATASERTIB-SPECIFIC CRITERIA

          -  History of type I or type II diabetes mellitus requiring insulin

               -  Patients who are on a stable dose of oral diabetes medication >= 2 weeks prior to
                  initiation of study treatment are eligible for enrollment

          -  Grade >= 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia

          -  History of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative
             colitis) or active bowel inflammation (e.g., diverticulitis)

          -  Lung disease: pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis,
             cystic fibrosis, aspergillosis, active tuberculosis, or history of opportunistic
             infections (pneumocystis pneumonia or cytomegalovirus pneumonia)

          -  Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5
             drug-elimination half-lives, whichever is longer, prior to initiation of study drug
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Recommended phase II dose (RP2D) of ipatasertib (Phase I)
Time Frame:Up to 28 days
Safety Issue:
Description:Tables will be created to summarize all toxicities and side effects by grade, attribution, dose, course (cycle 1 versus [vs] later cycles), organ and severity. Rates and associated 95% confidence limits will be estimated for dose-limiting toxicities (DLTs) at the RP2D, clinical benefit, response, and PIK3CA mutation rate.

Secondary Outcome Measures

Measure:Toxicities Evaluation
Time Frame:Up to 28 days
Safety Issue:
Description:The toxicities of treatment will be evaluated. Tables will be created to summarize all toxicities and side effects by grade, attribution, dose, course (cycle 1 vs later cycles), organ and severity.

Details

Phase:Phase 1/Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:City of Hope Medical Center

Last Updated